drugset
Drugs / omidubicel
last change May 2025 re-read 2 minutes ago

omidubicel

also known as NiCord · CordIn · Cultured fraction, CF · Ex vivo Expanded and Activated Haploidentical Donor NK Cells · Omidubicel component of omisirge · Omidubicel, cultured fraction · omidubicel-onlv

Cell therapy

Developed for
myelodysplastic syndrome · acute lymphoblastic leukemia · acute myeloid leukemia · aplastic anemia · chronic myeloid leukemia · hematopoietic and lymphoid cell neoplasm · Hodgkins lymphoma · inherited hemoglobinopathy
+2 more · neuroblastoma · osteosarcoma
Investigated by
Gamida Cell ltd · Midwest Athletes Against Childhood Cancer, Inc. (MACC Fund) · National Cancer Institute (NCI) · National Heart, Lung, and Blood Institute (NHLBI) · Solving Kids' Cancer · The Catherine Elizabeth Blair Memorial Foundation / GWCF
+2 more · University of Wisconsin, Madison · Wade's Army

Trials 7 · a red edge is where a trial was stopped

today NCT04260698 · Ph 3 NCT03209869 · Ph 1 NCT03173937 · Ph 1/2 NCT02730299 · Ph 3 NCT01816230 · Ph 1/2 NCT01590628 · Ph 1/2 NCT01221857 · Ph 1/2
20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03209869 Mar 2018 → Sep 2022 neuroblastoma, osteosarcoma University of Wisconsin, Madison Withdrawn No outcome recorded
Phase 1/24 trials
Phase 1/2 NCT03173937 Jun 2017 → Apr 2027 expected aplastic anemia, myelodysplastic syndrome National Heart, Lung, and Blood Institute (NHLBI) Recruiting No outcome recorded
Phase 1/2 NCT01816230 Apr 2013 → Jun 2017 acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome Gamida Cell ltd Completed No outcome recorded
Phase 1/2 NCT01590628 Sep 2012 → Sep 2018 inherited hemoglobinopathy Gamida Cell ltd Completed No outcome recorded
Phase 1/2 NCT01221857 Nov 2010 → Sep 2012 Hodgkins lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome Gamida Cell ltd Completed No outcome recorded
Phase 32 trials
Phase 3 NCT04260698 Jul 2020 → May 2025 hematopoietic and lymphoid cell neoplasm Gamida Cell ltd Completed No outcome recorded
Phase 3 NCT02730299 Dec 2016 → Apr 2021 acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome Gamida Cell ltd Completed No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as omidubicel ClinicalTrials.gov intervention name — accepted as the source's own label NCT02730299 ↗
2

NCT03173937 ↗

NCT04260698 ↗
Known as CordIn “Omidubicel (former CordIn)” NCT03173937 ↗
Known as Cultured fraction, CF ChEMBL registry synonym — accepted as the source's own label CHEMBL4298190 ↗
Known as Ex vivo Expanded and Activated Haploidentical Donor NK Cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT03209869 ↗
Known as NiCord “NiCord® (omidubicel)” NCT02730299 ↗
3

NCT01221857 ↗

NCT01816230 ↗

NCT01590628 ↗
Known as Omidubicel component of omisirge ChEMBL registry synonym — accepted as the source's own label CHEMBL4298190 ↗
Known as Omidubicel, cultured fraction ChEMBL registry synonym — accepted as the source's own label CHEMBL4298190 ↗
Known as omidubicel-onlv “A phase 3 trial (ClincialTrials.gov identifier NCT02730299) of omidubicel-onlv, a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy manufactured from a...” PMID 37703995 ↗ Sep 2023
Action Deplete “are still able to effectively kill the cancer cells” NCT03209869 ↗
Modality Cell therapy “NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells.” NCT01221857 ↗
Route Other “transplantation of NiCord®” NCT01816230 ↗